Klinikum Altenburger Land GmbH — Clinical Trial Site

17 Registered trials

9 Currently recruiting

Organisation

Klinikum Altenburger Land GmbH

Location

Altenburg, Germany

Identifier

ORG-100025896

Address

Am Waldessaum 10, 04600, Germany

Departments

Klinik für Hämatologie, Onkologie und Palliativmedizin
Klinik für Neurologie
Klinik für Neurologie/ Neurologische Intensivmedizin
Klinik für Orthopädie und Unfallchirurgie, Klinikum Altenburger Land, Altenburg
Klinikum Altenburger Land GmbH
NA
Neurologie
Neurologie / Studienzentrum
Neurology
Neurology and Neurological intensive care unit

Clinical trials at this site (17)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC Pending

2025-521130-28-00 generalized myasthenia gravis 5
Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting

2025-522455-26-00 Acute Ischemic Stroke 9 2025-12-17
Assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke. Recruiting

2024-519551-29-00 Acute cerebral ischemic stroke 5 2025-08-21
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants Recruiting

2025-521762-99-00 acute ischemic stroke 5 2026-03-09
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid… Recruiting

2025-522395-92-00 metastatic oeso-gastric adenocarcinoma 5 2025-12-15
Phase I/IIa study to test the safety and efficacy of MSC from umbilical cord tissue (UC-MSC) for the treatment of cartilage damage in the kn… Recruiting

2024-517684-23-00 Cartilage defect of the knee joint 7 2025-10-23
A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability a… Recruiting

2024-518563-35-00 Alzheimer's Disease 4 2025-08-25
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting

2024-519521-37-01 Acute ischemic stroke 10 2025-07-30
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Ended

2022-501890-38-00 acute ischemic stroke 4 2024-02-16
BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug… Ended

2022-502001-15-00 Acute Ischemic Stroke (AIS) 4 2023-12-05
A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran… Ended

2023-503793-20-00 Prevention of ischemic stroke in patients post acute no 5 2023-01-18